Joseph S. Zakrzewski

Joseph S. Zakrzewski discloses dealings in 5 companies, chiefly Cyteir Therapeutics, Inc., AN2 Therapeutics, Inc. and Acceleron Pharma Inc. The record holds 18 filings, for trades running from 22 June 2021 to 14 August 2026.

In open-market terms, that means 9 purchases worth €189k on one side and 1 sale worth €1.8M on the other. Netting one side against the other leaves €1.6M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 3 share grants and 1 option exercise.

Half of the purchases are above €19k and half below. 4 out of 9 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

On 14 August 2026 came the latest disclosure, a transaction in AN2 Therapeutics, Inc. The last insider purchase was made public on 27 November 2024, 690 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.